Northland Securities Thinks Opiant Pharmaceuticals Inc’s Stock is Going to Recover


Northland Securities analyst Carl Byrnes maintained a Buy rating on Opiant Pharmaceuticals Inc (OPNT) today and set a price target of $42. The company’s shares closed yesterday at $13, close to its 52-week low of $9.98.

According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -9.3% and a 29.8% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on Opiant Pharmaceuticals Inc is a Moderate Buy with an average price target of $40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.55 and a one-year low of $9.98. Currently, Opiant Pharmaceuticals Inc has an average volume of 20.24K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts